Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gowen

Showing results (671-680 of 681) with videos related to

Pageof 69
Sort By:
Science Translational Medicine|June 5, 2020
Immune landscapes predict chemotherapy resistance and immunotherapy response in acute myeloid leukemiaJayakumar Vadakekolathu, Mark D Minden, Tressa Hood, et al.
Immunity|November 14, 2025
FOXP3 expression depends on cell-type-specific cis-regulatory elements and transcription factor circuitryJennifer M Umhoefer, Maya M Arce, Sivakanthan Kasinathan, et al.
The Oncologist|June 2, 2016
Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ HybridizationSiraj M Ali, Thomas Hensing, Alexa B Schrock, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 15, 2018
RET fusions in a small subset of advanced colorectal cancers at risk of being neglectedF Pietrantonio, F Di Nicolantonio, A B Schrock, et al.
The Journal of Biological Chemistry|May 24, 2000
Potent and selective nonpeptide inhibitors of caspases 3 and 7 inhibit apoptosis and maintain cell functionalityD Lee, S A Long, J L Adams, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 7, 1998
Design of potent and selective human cathepsin K inhibitors that span the active siteS K Thompson, S M Halbert, M J Bossard, et al.
Cancer Discovery|May 15, 2015
Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitorsGarrett M Frampton, Siraj M Ali, Mark Rosenzweig, et al.
Nature|June 15, 2018
Author Correction: Discovery of stimulation-responsive immune enhancers with CRISPR activationDimitre R Simeonov, Benjamin G Gowen, Mandy Boontanrart, et al.
Nature|August 31, 2017
Discovery of stimulation-responsive immune enhancers with CRISPR activationDimitre R Simeonov, Benjamin G Gowen, Mandy Boontanrart, et al.
Journal of Medicinal Chemistry|April 20, 2001
Azepanone-based inhibitors of human and rat cathepsin KR W Marquis, Y Ru, S M LoCastro, et al.
Pageof 69

Showing results (671-680 of 681) with videos related to

Sort By:
Pageof 69
Science Translational Medicine|June 5, 2020
Immune landscapes predict chemotherapy resistance and immunotherapy response in acute myeloid leukemiaJayakumar Vadakekolathu, Mark D Minden, Tressa Hood, et al.
Immunity|November 14, 2025
FOXP3 expression depends on cell-type-specific cis-regulatory elements and transcription factor circuitryJennifer M Umhoefer, Maya M Arce, Sivakanthan Kasinathan, et al.
The Oncologist|June 2, 2016
Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ HybridizationSiraj M Ali, Thomas Hensing, Alexa B Schrock, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 15, 2018
RET fusions in a small subset of advanced colorectal cancers at risk of being neglectedF Pietrantonio, F Di Nicolantonio, A B Schrock, et al.
The Journal of Biological Chemistry|May 24, 2000
Potent and selective nonpeptide inhibitors of caspases 3 and 7 inhibit apoptosis and maintain cell functionalityD Lee, S A Long, J L Adams, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 7, 1998
Design of potent and selective human cathepsin K inhibitors that span the active siteS K Thompson, S M Halbert, M J Bossard, et al.
Cancer Discovery|May 15, 2015
Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitorsGarrett M Frampton, Siraj M Ali, Mark Rosenzweig, et al.
Nature|June 15, 2018
Author Correction: Discovery of stimulation-responsive immune enhancers with CRISPR activationDimitre R Simeonov, Benjamin G Gowen, Mandy Boontanrart, et al.
Nature|August 31, 2017
Discovery of stimulation-responsive immune enhancers with CRISPR activationDimitre R Simeonov, Benjamin G Gowen, Mandy Boontanrart, et al.
Journal of Medicinal Chemistry|April 20, 2001
Azepanone-based inhibitors of human and rat cathepsin KR W Marquis, Y Ru, S M LoCastro, et al.
Pageof 69